Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study

References

• Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707–14
   Google Scholar
• Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch Intern Med 1981;141:1128–31
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8–15
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124(Suppl):S11–S20
   Google Scholar
• Goldbourt U, Yaari S, Medalie JH. Isolated low HDL-cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17: 107–13
   Google Scholar
• National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;17:3143–421
   Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601–10
   Google Scholar
• Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. Lancet 2005;366:1059–62
   Google Scholar
• Grundy SM. Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Arterioscler Thromb Vasc Biol 2005;25:2243–4
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. New Engl J Med 2001;345:1583–92
   Google Scholar
• Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New Engl J Med 1990;323:1289–98
   PubMed Web of Science ®Google Scholar
• Brown BG. Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy Eur Heart J 2005;7(Suppl F):F34–F40
   Google Scholar
• Kastelein JJP. The realities of dyslipidaemia: what do the studies tell us? Eur Heart J 2005;7(Suppl F):F27–F33
   Google Scholar
• Abourjaily HM. A review of Niaspan, an extended-release niacin. Nutr Clin Care 2001;4:250–5
   Google Scholar
• Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004;5:1385–98
   PubMed Web of Science ®Google Scholar
• McGovern ME. Niaspan®: creating a new concept for raising HDL-cholesterol. Eur Heart J 2005;7(Suppl F):F41–F47
   Google Scholar
• Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998;47:1097–104
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110: 3512–7
   Google Scholar
• Grundy SM, Vega GL, McGovern ME, et al.;Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med 2002;162: 1568–76
   Google Scholar
• Morgan JM, Capuzzi DM, Guyton JR, et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther 1996;1:195–202
   PubMedGoogle Scholar
• Goldberg A, Alagona Jr P, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85: 1100–5
   PubMed Web of Science ®Google Scholar
• Niaspan® Prescribing Information. Merck KGaA, Germany
   Google Scholar
• McKenney J. Niacin for dyslipidemia: considerations in product selection. Am J Health-Syst Pharm 2003;60:995–1005
   PubMed Web of Science ®Google Scholar
• Wilkin JK, Wilkin O, Kapp R, Donachie R, Chernosky ME, Buckner J. Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol Ther 1982;31(4):478–82
   PubMed Web of Science ®Google Scholar
• Guyton JR, Capuzzi DM. Treatment of hyperlipidemia with combined niacin–statin regimens. Am J Cardiol 1998;82:82U–84U
   Google Scholar
• Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998;82:74U–81U
   Google Scholar
• Tato F, Vega GL, Grundy SM. Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipo-protein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiol 1998;81:805–7
   Google Scholar
• Dalton TA, Berry RS. Hepatotoxicity associated with sustained-release niacin. Am J Med 1992;93:102–4
   PubMed Web of Science ®Google Scholar
• McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. J Am Med Assoc 1994;271:672–7
   PubMed Web of Science ®Google Scholar
• Psaty BM, Furberg CD, Ray WA, Weiss NS. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. J Am Med Assoc 2004;292:2622–31
   PubMed Web of Science ®Google Scholar
• Grundy SM, Vega GL, McGovern ME, et al. Comparative effects on lipids and glycemic control of niacin extended-release/lovastatin or fenofibrate in patients with diabetic dyslipidemia. Abstract 29-LB, presented at the 64th Scientific Sessions of the American Diabetes Association, June 4–8, 2004, Orlando, Florida, USA
   Google Scholar
• Balkau B, Charles MA, Drivsholm T, et al.;European Group For The Study Of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002;28:364–76
   Google Scholar
• Balkau B, Vernay M, Mhamdi L, et al.;D.E.S.I.R. Study Group. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab 2003;29: 526–32
   Google Scholar
• Devroey D, Velkeniers B, Betz W, Kartounian J. The prevalence of low levels of HDL-cholesterol among patients treated with lipid-lowering drugs. Br J Cardiol 2003;10:50–5
   Google Scholar
• Tervahauta M, Pekkanen J, Kivinen P, et al. Prevalence of coronary heart disease and associated risk factors among elderly Finnish men in the Seven Countries Study. Atherosclerosis 1993;104:47–59
   PubMed Web of Science ®Google Scholar
• Taskinen MR. Diabetic dyslipidemia. Atheroscler 2002;3(Suppl):47–51
   Google Scholar